Season 6 of Surfing The MASH Tsunami
S6.14.3 – Louise and Roger React to Empowered SLD Patient Advocates
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
S6.14.2 – Goals of the Stephen A. Harrison Patient Advocacy Fellowship Program
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
S6.14.1 – How the Harrison Patient Advocacy Fellowship Came To Be
In this conversation, we learn about how the Stephen A. Harrison Patient Advocacy Fellowship Program started and meet the program organizers and five of the initial Fellows.
S6.14 – Introducing the Dr. Stephen A. Harrison Patient Advocacy Fellowship Program
Louise Campbell and Roger Green interview Wayne Eskridge and Elena Samsonova of the Fatty Liver Foundation and five of the first class of Harrison fellows about the new Dr. Stephen A. Harrison Patient Advocacy Fellowship program.
S6.13.3 – Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism
Roger Green drives this conversation, which focuses on two issues: impact of US government chaos on the MASH community and how competition might evolve in the in-office scanning market.
S6.13.2 – Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease
Co-authors Aleksander Krag and Stine Johansen discussed their recent paper, “Screening for Advanced Liver Disease”, which has been accepted for publication and popsted on line by The Lancet.
S6.13.1 – Major Issues: A More Integrated Approach to MASH Patient Management
Louise Campbell drives this conversation, which focuses largely on issues related to MASH patient management. Her general point is that we need to take a more holistic look at MASH patient management, including self-management. Jörn Schattenberg and Roger Green share comments and questions.
S6.13 – Locating MASH Patients, Population Screening for Advanced Disease, Impact of Washington on Americans’ Health
The co-hosts continue their look at major MASH stories from the first half of 2025 and two co-authors from a recent Lancet article on advanced liver screening join Roger Green to discuss their article.
S6.12.3 – After the Semaglutide Approval: What Next For MASH Therapy?
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval on MAH therapy in the U.S. This conversation covers the larger, downstream changes we will see in how MASLD and MASH are treated in the U.S.
S6.12.2 – After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers how the healthcare system will manage the tsunami of new patients resulting from increases in disease education and publicity.
S6.12.1 – After the Semaglutide Approval: Impact on Patients and Pharmacotherapy
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers pharmacotherapy choices and the benefits this decision offers for patients.
S6.12 – A Second US Drug Approval! What Semaglutide’s Success Portends For MASLD Care in the US
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.
S6.11.3 – Expert: Emily Andaya Asks Why There Is No “L” In the (Multi-Metabolic) CKM Initiative
Dr. Emily Andaya joins Louise Campbell and Roger Green to discuss the American Heart Association’s CKM initiative and why she believes it should include “L” for liver.
S6.11.2 – Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
S6.11.1 – Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics
Physicians Who Run Multi-Metabolic Clinics in the US and Spain Join Louise Campbell To Discuss Their Clinics (Part I)
S6.10.3 – Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients
Predictive Health Intelligence Medical Director Tim Jobson joins Louise Campbell and Roger Green to provide an update on PHI’s Somerset project and other activities.
S6.10.2 – Newsmakers: LiverRight Launches America’s First Virtual Hepatology Clinic
LiverRight CEO Brandon Tudor and Chief Medical Officer Alexander Lalos join Roger Green to discuss the launch of America’s first virtual hepatology clinic and the reason they created it.
S6.10.1 – FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans
First Six Months, Part I: Jörn Schattenberg cites two recent papers to describe the role proteomics might play in tailoring patient treatment plans.
S6.10 – New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening
Jörn Schattenberg, Louise Campbell and Roger Green discuss how future NITs can help prescribers decide where to focus therapy, LiverRight executives describe the first virtual hepatology clinic and simple large-scale data analysis identifies high-risk liver patients unaware of their risks.
S6.9.3 – Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research
In this conversation from April, Naim Alkhouri joins Roger Green to reminisce about his long relationship with Stephen Harrison and announce his (then) new role as Chief Academic Officer at Summit Clinical Research.
S6.9.2 – Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge
Fatty Liver Alliance President Mike Betel joined Roger Green to share some results and lessons from his 3rd Annual 30-day Glucose Challenge.
S6.9.1 – SLD ThinkTank 2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play
Behavioral Change consultant Dr. Kristina Curtis joins Jörn, Louise and Roger to discuss the unique challenges associated with weight loss through dieting and nutrition and ways government can support this effort.
S6.9 – Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and Medical Education
Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to wrap up the Steatotic Think-Thank on SLD, Mike Betel shares lessons from his 30-day Glucose Challenge, and Naim Alkhouri remembers Stephen Harrison while sharing his vision for the future of clinical trials and medical education.
S6.8.3 – Deep Dive into Drug Development IV: Other Modes of Action; Metabolic vs. Pleiotropic Effects
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss other agents in development with unique modes of action and the ways that metabolic vs. pleiotropic effects will drive future drug choices.
S6.8.2 – Newsmaker: GLI President & CEO Larry Holden Discusses Changes in Washington & How We Can Proceed
Global Liver Institute President and CEO Larry Holden joins Roger Green to discuss policy changes in Washington, some potential effects for the liver community, and ways to preserve what is possible.
S6.8.1 – SLD Think Tank 2025 Part II: Complexities & Challenges of Behavior Change
Behavioral Scientist Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss highlights of #SLDThinkTank2025. This conversation focuses on the kinds of feedback and activities most likely to produce successful behavioral change.
S6.8 – Hybrid Interventions; Washington Challenges / Two-Target Treatment
This diverse episode includes a discussion of effective behavioral therapies, a look at drug development we did not discuss in prior episodes, and a sober discussion on how to do our best in addressing the important Washington Challenges under Trump and RFK Jr.
S6.7.3 – Deep Dive into Drug Development, Part III: NITs in Drug Development
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss the current and future roles of NITs in Drug Development.
S6.7.2 – Newsmaker: Patient Advocate Jose Willemse on Drug Screening in Amsterdam and Patient-Centered Care
This week’s Newsmaker is Dutch Liver Patients Association President Jose Willemse. She discusses the patient screening program at the EASL Congress 2025 and the general idea of patient-sensitive dialogue with treaters.
S6-7.1 – SLD ThinkTank 2025 Part I: Hybrid Interventions Integrate AI and Human Care
Behavioral Scientist Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss highlights of the Global Think Tank on SLD. This conversation focuses on the program’s history and different ideas on behavioral interventions.
S6.7 – Barcelona SLD Conference Highlight: NITs in Drug Development
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
S6.6 – Remembering Stephen Harrison and His Many Contributions to MASH
On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
S6.5.3 – Expert: Scott Friedman on Gene Therapy and Advances in Liver Science
This week’s expert, hepatologist and Key Opinion Leader Scott Friedman, discusses the increasing acceptance of gene therapy in liver disease, evolving knowledge about the diversity of stellate cells and other advances in basic liver science. He closes with a request that all listeners do whatever we can to support NIH funding of science.
S6.5.2 – Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom
This week’s Newsmaker is hepatologist and key opinion leader Naga Chalasani of Indiana University. He discusses a recent article his group published in Hepatology Communications titled Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting.
S6.5.1 – Roundtable: FGF-21s and A Promising Future on Cirrhosis
The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.
S6.5 – Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies
SurfingMASH kicks off a month of Drug Development stories looking at FGF-21s and the future of therapies for cirrhosis and MASH, plus a paper on real-world resmetirom prescribing.
S6.4.3 – Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment
This week’s expert, hepatologist and Key Opinion Leader Mazen Noureddin, discusses exciting advances in MASH and cirrhosis drug development for multiple modes of action.
S6.4.2 – Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates
This week’s Newsmaker is Mike Betel, Founder of the Fatty Liver Alliance. He discusses some of the reasons that key MASLD Patient Advocates like himself are getting more visibility at a broader swath of global conferences and the messages he delivers at the conferences he attends.
S6.4.1 – MASLD Drugs, SLD Spectrum Insights Suggest Bright Future
This concluding segment of the Emerging Trends Conference 2025 Roundtable expresses optimism about the future for Steatotic Liver Disease patients, with a better understanding of how to treat based on viewing steatotic liver disease as a spectrum and an accompanying explosion of the number and diversity of drugs available to treat patients with MASLD, MetALD and ALD.
S6.4 – Reasons for Optimism in MASLD Drug Development and Patient Advocacy
SurfingMASH concludes its coverage of the Emerging Trends Conference looking at an encouraging future in MASLD drug development and increasing interest in patient advocacy.
S6.3.3 – Expert: GLI’s Jeff McIntyre discusses implications of FDA job cuts on MASH Drugs
This week’s expert interview with Jeff McIntyre of the Global Liver Institute took place one day after news media reported on high-level job cuts at FDA. Jeff and Roger discuss possible implications for MASH drug and diagnostic development and the steps patients can take to protect their rights and health.
S6.3.2 – Newsmakers: HistoIndex’s Yukti Choudhury Discuses Their New Product, FibroSIGHT
This week’s Newsmaker is Yukti Choudhury of HistoIndex, discussing FibroSIGHT, the company’s new diagnostic for use in clinical practices.
S6.3.1 – Roundtable: Spotting Tomorrow’s Trends in Today’s MASLD Studies
This week’s Roundtable segment focuses on what we can learn from today’s trial results about trends for the future and asks questions about ALD trial design.
S6.3 – Drugs and Diagnostics Evolve as the FDA Devolves
SurfingMASH explores the future evolution of drug therapy, a new biopsy-enhancing option for clinical use and the implications of FDA and NIH job cuts.
S6.2 – MetALD Epidemiology, MASLD Mortality and a PCP “Unicorn”
MASLD takes center stage in this week’s episode, exploring how alcohol, diet, and genetics shape disease outcomes and long-term mortality. From Swedish data on cause-specific deaths to personal stories of liver-focused care, the insights hit hard—and help chart a better path for patient health.
S6.1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom
SurfingMASH covers two major February conferences: the AASLD Emerging Trends Conference and the Desert Liver Conference, with similar multispecialty perspectives on the entire range of steatotic liver diseases, while Jörn Schattenberg discusses how his practice (and all of Europe) is preparing for resmetirom.
Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.
